MRK - CymaBay Seladelpar Data And Other News: The Good Bad And Ugly Of Biopharma
CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder
CymaBay Therapeutics (CBAY) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta. The drug candidate has shown anti-inflammatory and anti-cholestatic effects in clinical studies for PBC.
The reported data pertains to patients after 1 year of treatment with the drug candidate. The results demonstrated it to have impact on key patient metrics such as measures of pruritus and quality of life. The patients